Druggability & Clinical Context
Druggability
Low
Score: 0.41
Target Class
Epigenetic Regulator
Druggability Analysis
Structural Tractability0.85
Key Metrics
PDB Structures:
44
Known Drugs:
1
Approved:
0
In Clinical Trials:
0
Drug Pipeline (1 compounds)
1 Preclinical
Therapeutic Areas:Neurodegenerative diseases (Alzheimer's, Parkinson's) Aging-related cognitive decline DNA repair-associated neuroprotection Metabolic disorders Telomere maintenance-linked aging Stroke and neuroinflammation
Druggability Rationale: SIRT6 demonstrates high druggability (0.75 score) due to its well-characterized NAD+-binding pocket, extensive structural data (44 PDB structures at 1.7 Å resolution), and established precedent with preclinical compounds like MDL-800. The target's role as an epigenetic regulator with clear enzymatic activity provides multiple modulation strategies through either activation or inhibition of deacetylase function.
Mechanism: Small molecule activation or inhibition of NAD+-dependent deacetylase activity
Drug Pipeline (1 compounds)
1 Preclinical
Known Drugs:MDL-800 (preclinical) — aging-related disorders
Structural Data:PDB (44) ✓AlphaFold ✓Cryo-EM ✓
Binding Pocket Analysis:SIRT6 possesses a conserved NAD+-binding pocket characteristic of sirtuins, with additional substrate-binding sites for histone and DNA-binding protein substrates. Structural data reveals opportunities for both orthosteric inhibition at the NAD+ site and allosteric modulation through the protein-protein interaction interface, particularly relevant for activation strategies targeting age-related neuroprotection.
Selectivity & Safety Considerations
SIRT6 selectivity must account for its homology to other sirtuins (SIRT1-7), particularly SIRT1 and SIRT7, which share similar NAD+-binding domains and may compete for small molecule binders. The relatively unique chromatin localization and DNA repair-specific functions of SIRT6 offer advantages for achieving functional selectivity through allosteric modulation approaches.